Q4 EPS Estimate for Globus Medical Lowered by Analyst

Globus Medical, Inc. (NYSE:GMED) – Analysts at Zacks Research dropped their Q4 2027 earnings per share estimates for Globus Medical in a report issued on Thursday, October 29th. Zacks Research analyst Team now forecasts that the medical device company will post earnings of $1.35 per share for the quarter, down from their previous estimate of $1.37. Zacks Research has a “Strong-Buy” rating on the stock. The consensus estimate for Globus Medical’s current full-year earnings is $4.99 per share.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, August 6th. The medical device company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.10 by $0.24. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. The company had revenue of $789.61 million for the quarter, compared to analyst estimates of $782.88 million. During the same quarter in the prior year, the company earned $0.86 earnings per share. Globus Medical’s revenue was up 5.9% compared to the same quarter last year. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS.

Several other equities analysts also recently weighed in on the company. Wells Fargo & Company dropped their price target on Globus Medical from $103.00 to $99.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Royal Bank Of Canada cut their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a report on Thursday, October 1st. Truist Financial cut their price objective on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating on the stock in a report on Thursday, July 16th. UBS Group initiated coverage on shares of Globus Medical in a research report on Tuesday, July 28th. They issued a “neutral” rating and a $82.00 target price on the stock. Finally, BMO Capital Markets started coverage on shares of Globus Medical in a report on Wednesday, July 8th. They issued an “outperform” rating and a $94.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $99.46.

Globus Medical Stock Up 0.2%

NYSE:GMED opened at $79.59 on Monday. Globus Medical has a 52-week low of $60.26 and a 52-week high of $101.40. The company has a market capitalization of $10.69 billion, a PE ratio of 16.15, a price-to-earnings-growth ratio of 1.28 and a beta of 0.98. The stock has a fifty day simple moving average of $77.40 and a 200-day simple moving average of $83.39.

Insider Transactions at Globus Medical

In other Globus Medical news, Director James R. Tobin sold 30,000 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $74.58, for a total transaction of $2,237,400.00. Following the completion of the sale, the director owned 15,000 shares of the company’s stock, valued at approximately $1,118,700. The trade was a 66.67% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Stephen Zarrilli sold 25,000 shares of the company’s stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $87.04, for a total value of $2,176,000.00. Following the sale, the director owned 25,000 shares of the company’s stock, valued at $2,176,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 18.38% of the stock is currently owned by insiders.

Institutional Trading of Globus Medical

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Janus Henderson Group PLC raised its position in Globus Medical by 4.5% in the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP lifted its stake in shares of Globus Medical by 1.9% during the first quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock worth $263,477,000 after purchasing an additional 58,000 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Globus Medical by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after buying an additional 33,976 shares during the period. Boston Trust Walden Corp boosted its position in shares of Globus Medical by 4.4% in the third quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock worth $123,071,000 after buying an additional 69,782 shares during the period. Finally, The Manufacturers Life Insurance Company boosted its position in shares of Globus Medical by 2.8% in the first quarter. The Manufacturers Life Insurance Company now owns 1,132,278 shares of the medical device company’s stock worth $97,557,000 after buying an additional 30,412 shares during the period. Institutional investors and hedge funds own 95.16% of the company’s stock.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.